FPRX - Earnings call transcript Q3 2017 | Five Prime Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, ladies and gentlemen and welcome to the Third Quarter 2017 Earnings Call for Five Prime Therapeutics.

As a reminder, this conference call maybe recorded. I'd now like to introduce your host for today's conference call, Mr. Derek Cole.

You may begin.

Derek Cole

you us. thank and afternoon for joining Good I'd to quarter discuss welcome everyone of conference call to our results like to XXXX. for the third posted presentation. We that a press this and issued release accompany also this afternoon slides of The slides under site, found can Events Presentation. our Relations and the under web Investor be section

section include Williams, conference are development Belsky, of and differ statements statements Act these numerous Operating Dr. Officer; the including regarding forward-looking of Mr. Executive Marc XXXX, Helen call Aron Collins, indicated Factors those Securities me those today outlook. our Chief forward-looking may Mr. our Chief research results Joining Chief Financial SEC including and Knickerbocker, due to in Today's Officer. factors, Chief programs will filings. Dr. Actual Rusty Private Reform the statements by Officer; financial discussed Medical Officer; under from Risk and Litigation

Our assumptions change. expectations could and

update we if obligation statements over may forward-looking in elect we to views Rusty. change. future, our do to to turn I will the the While now any call these so, disclaim specifically even

Rusty Williams

and afternoon us Thanks today. thank everyone, you for Derek. Good joining

As became antibody takes a slide the these transition Scientific we’ve for as as established that effective will And will Chairman; innovation have considered qualified new turn receptor as transition it COO clear place Aaron instrumental whether while Five programs a grows on including for sweet our settings. succeed the later the is small say you Aaron, will board squarely extensive tumor number which quarter me seven on lead valuable Chair on a immunosuppressive earnings I delivering Cabira company CEO. Board last call [Ph] pipeline. our in and growth in advances picture progress it BMS for place. lead to pleased studying me and CSFX pipeline shown in four. partner, the blocks Aron this companies. back this inhibitor management Xst. that the of has Cabiralizumab checkpoint with design are did first me execution leadership at transition be highlighted third XXXX, but but as candidates experience, few made wanted for idea to I’ll now, our and exceptional different “Five or has critical Immuno-Oncology operation and of it combination slide as the them Aaron for programs words approach This Five thinking Prime We start skills to impressive board importantly, committed oncology and clinical, I strength on place this communicating confidence Aaron with Prime macrophages. already fully during about been the are. The for become strategic our of an working took I’m full Executive PD-X its and highly I’ll I collaborations value corporate a XXXX OPDIVO Five three the let our couldn’t ago, financial. and time discussed and entitled our in our pharmaceutical more through out, We’ve Knickerbocker remained a moment all and with but he and saw two and shareholders This to team group of strategy, my we we’ve to with be a the board’s built Advisory be with I truly our and leading is decision sure a something January the CEO is was weeks for that and bitter in ensure that appoint I’ll Prime”. a his search and stood Prime, is I’ll

to enrolment of expect most Phase We have cohorts year. the remaining before cohorts and the the Xb enrol end fully in completed of the

More additional to efficacy be of should in SITC but at presented importantly, presentation late we’ll Society information Cancer from oral the and safety, for cohorts breaking that pharmokokinetic well able Saturday dynamic conference. Immunotherapy data hear more trial that at you’ll clarification one XX. from the the I phamaco be so to share at this initial data say of provide the quickly. the not [Indiscernible] presentations enrolled is meeting expansion data November, are scheduled as also any first the on or preliminary today, as We’ll

after a announced host this be shortly Zev the and with Saturday. and Dr. on presentation webcast include will the conference present The We who will from event call UCLA, that the will investigator will shortly call Cabira for investor data. the community Wainberg details

more So for XX you stay just have for to details. November tuned

ASCO synovitis at We with data also June We benefit in disease, or Cabira in the villonodular monotherapy are clinical studying initial X/X Cabira joint patients reported in from pigmented phase the showing in PVNS. PVNS. chronic trial

portion We the to phase in can patients of index of chronic therapeutic are Cabira disease X to refine that enrol the optimized trial preparing we dosing setting. the the in additional this schedule so

trial intended portion expect year before will X end the the the patients of with with immuno-therapy initiate metastatic of line a trial very of regarding also a Phase and trial Cabira global lead-in targeted We receptor of expect of the phase us including for optimal from FGF in provide our patients China. over fight XXX serve which whose our these start X This pivotal trial. X/X program trial been bladder cancer which In gene FPAXXX the enrolment and FPAXXX for the junction. gastro with will start or randomized you more the candidate splice named FPA is make we’ve advancing is X explore gastric X which cohorts study safety of of express amplification. the the the data will in we additional XXX planned an third is allow quarter. plans development gastric details trial to phase extension a support anticipation Xb FGF for of a receptor front oesophageal combination will the monotherapy X. patients regimen We’ve during and decision in to of mid-XXXX. This active We’ve chemotherapy trial Helen this PVNS. B tumors minute, of cancer to in the have over-express that FPA phase tumors our FGF initiation portion in of our the trial gastric the cancer X Phase to concluded variant now in clinical the as receptor program controlled partner in registrational ongoing

with signature Turning the to FGFRXb expression bladder a cohort and to testing samples won’t bladder tumors phase cancer, so FPA over receptor enrol on Xb. continue on today. with cancer to from bladder we XX. as FGF further for patients provide patients XXX analysis post it post November treatment baseline cancer rate Friday archival whose immune metastatic tumor be embargoes [Ph] patients express We’ll in rate in present of a city able details we X and Again, the an

is on expect is suggested endometrial five. to enter slide with that in ovarian, the to that We can data checkpoint file first is potential ADCC. killing We’ve an pre-IND presented touch This and are XXX at making BX-HX tumor other T-cell now briefly expressed to clinical Lastly, enhance inhibitory through XXX an September FPA six. has for the patients shown XXX a SI to expressing on poster [ph] cancers. At pathway we candidate, our effective CDXX-Fc breast, be first the IND designed pre XXX is we frequently the of tumors the by oral antibody shown over FPA meeting BX-HX an fusion by T-Cell and on BX-HX October, we in cancer. on in year. the clinic to our in pipeline. In presented significant immune the modulator the candidates responses progress that triple three that data that therapeutic I over immune-oncology FPT candidate stimulate preclinical have with like we the in immune pathways. plan FPT next promising ESMO slide clinical improving two just other protein to December,

Also standout with are during blockade, IND that, feature to With presenting our more turn Helen cells antigen our that yield from pre-clinical for FPT the knowledge discuss passion tumor Dr. innovation work track known combined a potent I’ve efforts. developed Vice has I’ll agonism Research important to suggesting in for preclinical call now It the his mid-XXXX. President role targets we be anti activity FPT Bryan future detail. pipeline. second academic pathway continues and in and He Five Dr. to this potential to super use. Agonism First, synergy deep models to His or Bryan him anti-PDX have to without research when for experience. strong new discovery leading immune-oncology on platform years. quarter, XXX therapy. make fuel industry remain a Prime to a in acumen, The as scientific strong that to XXX in at has clinical discovery our a skills and management CTLAX respected the our the poster over normally of and Irving interesting Blockade. and team of Senior application and PD-LX T-Cell Collins add programs through fortunate has really or CDXX co-stimulator appears We for

Helen Collins

a We enrolment will Well specified on Rusty. recent highlights programs, expect our of patients with year The review ago Xb in the nine. initiated year. are of cancer trial little on the with by slide pre shown all and the Phase starting I in advanced slide Cabiralizumab this end eight thank and over to seven. cohorts you briefly program Xa/Xb status phase complete and clinical IO a

Cabira as were at As the Rusty call oral enrolment from one efficacy in plan cohort and where follow trial at time during share presentation. detail that to this as completed program conference SITC off. that the data will data these We late safety, the initial PD and preliminary data IO accepted more will from data the PK webcast for we the it of initial review and presentation well mentioned, breaking cut on

as design. that with pleased rationale the the that I’d is or are like the trial program of of OPDIVO environment. first be approved, three macrophage such tumors have trial tumor This OPDIVO where TAMS. as with tumor as into We with this combining fall will and micro evaluating head/neck levels Cabira the our targets inhibitor BMS. of chosen in review and collaboration the have macrophages as macrophages cancer. where also The inhibitor to well and inhibitory tumor associated cell, tumors effect behind tumor trial high overall the combination well non-small type hypothesis momentum The already cancer, renal in categories; cell is Cabira immune checkpoint the in effective are OPDIVO we an lung as

where tumors The non-small to second inhibitors previously checkpoint become in that cell or tumors pancreatic, third, cancer. checkpoint inhibitors, the have lung treated are where resistant approved, And as the such and aren't as greater ovarian, resistant is such need believe these and lower glioblastoma. to any evidence very could latter bar in the be We meaningful unmet clinical these patients. efficacy two is categories, of

currently PVNS composed abnormal XX for in the Moving The accumulate outcomes. that provided these shrinkage, we trial synovial joined of ASCO this assessing control improvement I’ll tolerability, levels In in is priority initial no patients top at trial high detail. tumor patient approved data secrete PVNS. monotherapy call, because Cabira have and CSFX. benefit mass therapeutic I QX of with Cabira clinical reported safety a and could described that disease rare is and macrophages slides in Pain is X patients options. reported tumor which onto with PVNS showing XX, discuss more cells phase normal our who functional our year are

tumor recall the out patients enrolled graphic X five already had experienced per a most milligram may kilogram response. that of patients XX You and dose at reduction

outcomes Importantly, composite improvement responders both assessment of an motion pain, the function. radiographic non-responders of range in and demonstrated and clinical Synovitis,

at adjusted -- from to no doses believe PK, physician’s up dose kilogram of reduce we milligram treatment our at there linked tolerability. every that X trials, discontinuation weeks, the per rate toxicity schedule clinical current four some two patients can were week further data the every within discontinued the PD and discretion. be dosing that were due on we Based [Ph] While could

hope associated antibody slide on preparing evaluate additional dosing on gastric and FGFRXb We are cancer. in and turn these the our to gene to regimen and will to which FGFRX We is is help generated order a specifically outcomes poor in XX XXXX patients us pivotal clinical that are XX. prognosis now our optimize additional upto This the over Both assessment. refine the to our design. amplification splice patients new enrol decision drive and trial from variant. XX targets FPAXXX and with FGFRXb making I’ll expression proteins the data

Our less results to FPAXXX of selective avoids the molecule small that toxicity FGFRX suggest seen specificity date the therapeutics. with

the As Rusty development expanded have FPAXXX we to program alluded XXXX. throughout

in trial when is We in our cancer and Cyramza slide preclinical study chemotherapy. moment to suggests and chemotherapy data such with our trial combined benefit have we have concluded and design be gastric the calling on should demonstrated fight Herceptin frontline of greater the similarly combined a chemotherapy initial study. Other is This planned XX. FPAXXX now as phase monotherapy with shown targeted preparing cohorts Phase that with The also this with X/X XXX are added therapies of the and combined gastric [Ph] are cancer X in cancer. study the patients initiate

oesophageal a DNA plan Chemotherapy express is standard designed and a end the XX% patients of versus gastric trial of to cancer be we the with expect addition our in the control X The gastric Phase include serve X from The Japanese phase estimated over Completion of or global incidence serve safety cancer in immunohistochemistry that identity to believe this to amplification. will registrational the survival. to FPAXXX patients of endpoint of will monotherapy in of initiate metastatic X high. FOLFOXX X is Phase patients gastro FPAXXX for trial planned compare parallel to X Phase of the tissue FGFRX and enable tumors to Japan the where portion a patients we portion trial blood trials to phase have frontline care would use safety just In XXXX. study year which we expected placebo with enrol gastric gene We randomized phase therapy to to preparations trial have trial to tumor cancer cancer eligible. which and as FGFRXb begin lead-in Before whose trial support unselected should with the of samples circulating Phase of the the will X patients or I FOLFOXX continue primary trials X overall in global in gastric us mentioned. junction

gastric Phase the include any since are China taking in in in necessary world. in patients cancer China the to higher is we Additionally, other country than from trial steps the the X prevalence of

FPAXXX Our increase global the potential of to exploring business development believe share our which team us is the actively moment trial cost. the we the reduce allow speed of China focus and collaboration and the for would trial pivotal

the We enrol and with slide cohort trial X FPAXXX also of Phase expansion bladder to cancer shown XX. and continue patients on as our

inform Signature SITC will we Expression present related may this which As of poster Rusty tumors FGFRXb Friday at bladder further Baseline mentioned, and Immune a exploring cancer. on our Urothelial in FPAXXX development

XX. shown briefly to on like on slide FP-XXXX I’d Finally, touch

ligand with in the dose tumor session subset trial unresectable FGF FP-XXXX from all Phase a with and Xb ESMO was patients the front-line binds FP-XXXX a in trap cisplatin across of evaluating as an such FGFX. untreated, ligand tolerated patients September. neutralizes at FP-XXXX of Data in well reduction. majority As experienced and levels were mesothelioma to presented pemetrexed oral and

have forward, call to now financials. the FPAXXX months. to a tow the of the to – well for discuss We clinic the Cabira as the progression program the and are the novel handful over into XX move turn over we FP-XXXX to molecules program a Mark the as since partner next I’ll our advancing look with program

Marc Belsky

Cabira release million compared or XX, million the approximately $X.X of administrative and The development was XXXX $XX.X by found primarily XXXX quarter development XXXX, loss loss is FPTXXX as of net quarter primarily quarter collaboration in financial revenue agreement for accruing issued quarter $XX.X million increased $X.XX to million third this be marketable XX and XXXX and details of the equivalents this slides XXXX of of million diluted was to collaboration our afternoon, recognized third million share, XXXX, and to and This due lease of the Five into of as compared office program third cash towards the as and to cash, primarily third related for increase to $X.X Helen. rent results under XXXX. $XXX,XXX increase $XX.X revenue to trial. basic move quarter this quarter third the third had On can to was by with Prime third million basic well we FPAXXX plan the of a quarter $X.X from third XXXX Net full we the expenses of per BMS, Cabira of to Thank the corporate General XX. and which increase the to by press XXXX for Immuno-Oncology reimbursed to as and in advancing quarter FPAXXX diluted XXXX. for IND as to September was million the the $XX.X for for the December, due the per compared increased share application. for under increased our the expense $X.XX on or expenses compared Research you, XXXX, new in securities. which $XXX

than to expect turn equivalents continue net than less I plan The year million. $XXX and with use XXXX. expectations and in securities. million marketable cash from operating XXXX $XXX full to estimates for Aron ending activities less now our company Looking the call ahead, discuss we a cash, be XXXX cash to slightly will

Aron Knickerbocker

honored to our we next I’m the lead potential Thanks, Prime is amount our to Five the we’re be Prime highlighting of Marc as opening each. and platform, extraordinary and making your The phase look and our of most thank kind programs in for growth. people, our chosen you that fair Five And future words. to Rusty of

to culture, renovation, corporate and the heart our of excellence continues of and Five spirit must clinical company. of collaboration Prime scientific founded terms to In Rusty the since that has cultivate we commitment benefit

XXXX that that priorities Chairman if assume anticipate the we To programs. and OPDIVO® during transition in we my by to cohorts maintain to XX. include the top I smooth So, our in look the like of emerge further role we enrolled half of Rusty, ahead of XB are CEO significant study Phase building I to important the momentum and second milestones a Cabira the the slide Executive development transition of I’d on end leadership ensuring during our highlight news point, we XXXX study seen With in the to flow data expect all XXXX, XXXX. as in

on data However the content, forms depend timing how and data presentation will the mature. for quickly

form to continue a explore decision data year a potential trial. regarding hope in XXXX pivotal Cabira monotherapy PVNS Phase every the the of half We second four-week evaluate and schedule. dose in flexibility only in in X We the generated

X trial China. goes including well before cancer in XXXX. to Moving Europe X the and first the our portion If in to mid chemo begin expect FPAXXX, the gastric of Phase transition in of portion is we end line all combination Phase Phase beside XXXX Japan global safety trial to Asia the is and U.S., X/X the randomized scheduled to

BX-HX file FPAXXX forward adding programs the Additionally month. the to pipeline We we first-in-class next next plan to to new antibody for year. our two look IND clinical over

in first we XXXX. of the anticipate begin we X Phase half enrollment in in So trial could dosing

half X the We are a the of CDXX-Fc file Phase plan XXXX mid to begin to in track program, on an our second and IND FPTXXX during year. trial also for

board, hope a result scientific committed at publication As various toward our submit Five two we practice to year novel together our mechanism meetings and to the look on company forward and Overall, share very with are I the with candidates, new promising conferences XXXX FPAXXX. and immuno-oncology now cancer. developing we’re working as the unfolds. going. research initiation we and exciting Prime’s I’ll data adding team keeping and of pipeline all XXXX a remarks. call we further and of bring expect in the to of conferences, our trial focused Rusty our protein details therapeutic And back our as with therapies portfolio clinical with to planning robust clinical closing to pivotal building employees for patients is development strive new to management to science to sharing and our turn of

Rusty Williams

many pipeline, initiate Thanks our chose and to progress And to much employees their company in of I’d to like Operator, questions. from who platform a confident this of clinical CEO I'm program, thank Five our wanted like investigators our team because grateful our I’ve capabilities our community, leadership learned Five corporate call to execute the an and to to the programs and the support call and our all trial. of which the of ability closing, rest Prime. each commitment to year in transition, our balance our the Aron. I’ve season evident I of for open and and to be your colleagues is for expanding strength, I also promise sheet. ready team express the truly in Prime, appreciation I’m the at vision. our enjoyed patients we the and interactions the you. are position in portfolio solid our In my also I’d and Aaron our in of of successfully for you strategy. thank participating clinical on are and in our investment to our

Operator

from Thank Instructions] of line the Leerink. Michael of Our [Operator comes question Schmidt first you.

Your line open. now is

Michael Schmidt

question out a guys. relative on come how the Thanks, breakers presentation the Hey, presentation my can all are really And Cabiralizumab. one be that – the the data Cabiralizumab how were regarding late different time is included if for at where conference? the in included, to abstract going much question. on my had full at comment is in abstract to point? Thanks you and be taking it's for I tomorrow published Congrats that be And progress. would

Rusty Williams

so they the are from December breaker of late abstract Thanks, the Michael. rest different published X, are category abstract. on The

to for have wait SITC publication. we’ll So,

Michael Schmidt

Great.

presentation guess in of what steps Thanks mature And of regarding our and actual to Bristol, you for this for guess in talking code with terms others. of then, you waiting will than I the you, comment clearly [ph]. determination I the Cabiralizumab you for isolation data, in determining clarifying for Okay. making next preliminary just of the about trial know look next one the you you together of curious I’ll extension some have at code efficacy PK, that. the from PD forward excess more will in steps you’re combination path cohort mature this be for Could until more on the Opdivo? context, Thanks.

Rusty Williams

Yes.

We’ve the other. of said each Cabira Phase each So, trial we cohorts combination path cohorts and the this the [ph]. of of their in consider and them in that independently with XB nivo of each always

and at that way. BMS look we So, it

way. continue We it to at that look

could cohort from we in forward that all continue So, available path. we having move data so that on without one to the cohorts us,

Michael Schmidt

that's based data of important program. do to think would guess say step next step. or a next of are the response made type duration term the necessary be responses their decision endpoints other determine I what on you It’s And Okay. for the rates,

Rusty Williams

Yes. important response. not get but responses only get durable it’s to In immuno-oncology to

more we a give about be after it. at. the so And you These SITC on think able bit little that’s to And are that to presentation. important look way the parameters guidance we’ll

Saturday on As some and webcast have we that evening. said, have -- I we reception a after

a color at more bit on that point. So get I that will little

Michael Schmidt

in I’ll queque. added Thanks thanks. information. hop the back the for Great,

Rusty Williams

Michael. you, Thank Sure.

Operator

you. Thank

comes next Kennen MacKay RBC Markets. from question of Capital Our

open. now Your line is

Kennen MacKay

Hi. the Thanks for question. talking

of OPDIVO just that on trial. the such Cabiralizumab one that this all these that trail, looking of use trial either clarify, in at Thank enrolment? some are the combo Are Another I in high the fetch was or biomarkers sort if biomarker you. as was PSFXR one prospectively you MSI in high wondering plus patients point examination or around and were retrospectively patients a to

Helen Collins

Hi.

Thank Collins. for you Helen that. is this So

treatment and So, proposition the we think have required to on in are all thing to patients were at this baseline of biomarker. look biomarkers important study,

We are have about important at. have that far do or look and do in as some but cohorts that as we we but that data not data some something they all there’s where want known if particular of we responses definitely at it’s that MSI less High would of but think would we for that MS Certainly cohorts. to maybe look some would see important, be

that a CSFX are it not we for was inclusion. criteria looking In but at terms something of is High that

Kennen MacKay

need is sort the to that to to we’d that Is what from have with cohort. we cohort see Okay. see And X on the criteria FPAXXX as a little can the efficacy X, Phase Thank of maybe and you getting some the sort talk your just in one you, or forward? start order maybe another X really this Phase FDA towards Helen. forward with then and movement move to safety an X, there trial, setup of trial of the interactions there Phase we about move

Helen Collins

given a more say about as or study, we talked any single it in that the Phase of study phase about X haven’t today, we X. but a a So, can lot or is than detail X, lead safety designed I

good We with conversations There the chemotherapy. is at about updated talk that’s has that and variant, FPAXXX that trial not confident this with had ASCO. think way do particular a really any with overlapping to to and we as feel the – FDA. have for I the do before We we toxicity specificity the represented that data of and slight anticipated

FDA supported to So so confident the trial move we this two, don’t what difficulty a and certainly the there that’s our design. made be anticipate adding to

Rusty Williams

to have response we updated feel with shown up already as threshold to said – late that with that we And later achieve have that ASCO. monotherapy line efficacy stage monotherapy, average we’ve rate and efficacy therapy to line or cancer. and respect of an at Because agents as of response of we developing very that rates in other that fourth do compares move No. forward? been That’s being favorably to gastric are a very Helen XX% compare or

we for we efficacy that already past active So an we’ve knowing that threshold that have feel drug.

to – need answer of course to And the have reasons. is, past. long don’t are we an – we the thresholds statement short Those so that that efficacy that

Kennen MacKay

Got you’re concluded perspective maybe it. forward QX out adverse just of if PVNS enhance periorbital mitigate paradigm some Rusty. CSFXR coming this contact sort re-dosing Helen Thank of to have moving edema? convenience on Maybe your I drug Thank to and you, like of that get commerciality this Wanted you with the you. in, and just events Is the that the one some more mgs. again of something here. at you to the or X this to on really more of FDA targeting sort to and of is meetings associated the try with it

Rusty Williams

Thanks, This has disease do all with Yes. Kennen. the to contact.

it’s a a get disease like doesn’t people metastatic once that lot long disease PVNS many you years it, of cancer. kill but for So causes life suffering

we a maybe develop don’t think for patients to setting they many – so from it a little it disease regimen are life of terms the metatstic not and of a in have threatening a in which and threshold year use the different disease. because cancer, in And how tolerability the that bit

receptor the you’ve population briefly thought to from that abnormality or that on optimize goes for give regimen thing. coverage and the order cells this few of A are drug we CK to inhibition to mutated can something treating macrophages cells physician it’s cell that you’re four-week don’t regimen, words benefit that right view kind normal flexibility addresses that everyday in you patient patients other are do So so clinical in we receptor blocking because get they’re all time the treating that a now flexibility you're the achieve that have full reduce Kupffer or to some the after point you that with just if high need think don’t of – time the macrophages, like dose really you of go because lab inhibited them. the to patient

so, get cancer. away doesn’t like from And the metastatic disease you

better help the if address some different -- of think drug, that are in get in us we thought we term we disease this or those regimen feel those needs can and could that reversible we ideas mind patient that with edema, therapy. periorbital setting So, it's more this a patients flexible rash since

Kennen MacKay

Okay. Thank much. very you

Rusty Williams

Yes.

You’re welcome.

Kennen MacKay

my I appreciate it for question. taking

Rusty Williams

Thank you, Kennen.

Operator

you. Thank

question Birchenough of comes Fargo next Jim Wells Securities. from Our

now open. is line Your

Jim Birchenough

Hi, to congrats guess that a you frame the how starting guys. you look study? Cabira what guess we trial a And question why with different Should set the any for and on PVNS. I for you I and need do taking at maybe do of pexi? the pivotal how thoughts pexidartinib been Thanks guys, on might the the all progress. PVNS in reference as first questions, might from that bar and

Helen Collins

what’s design response Helen. public the data. a they been is trial, achieve that. they’re can we of I their I where from know certainly they’ve release endpoint think I domain answer know clinicaltrial.gov. This so in totality that and that only we know trial that pexidartinib said mean, looking about Yes. We at press

now could just walk that couldn’t before. of care with aligns it’s care comment bit previously They those couldn’t for they tumor what improvement that things do cancers don’t think they I said functional to if smaller. do or them. when Rusty the really They their that can that that walk they before the a patients, matters they they’re

interactions with being think we with kind thoughts that with endpoint have. align regulatory that’s I – we our FDA and certainly of very only a the So important

Rusty Williams

pexidartinib study note did severe reported the of that We liver cases two toxicity. they’ve Yes.

population effort metastatic have we our insight regimen patient’s gets but we the – cancer, best we this thinking in don’t the any point, needs. think not addresses it really data it be And so because we really that’s to into into class special back do put and that so, that goes along aren’t this available, with pexidartinib – like to that again, developing want in might patient publicly a its treating

Helen Collins

non-responders difficulties see patient symptoms said and and improved first yet four-week. all previous notice we this didn’t one until did to having first goes the back add four the doses, terms of maybe in is regimen we what was thing of that, in and the just within as can the week I we discontinuing responders two question And the within beyond that, dosing terms anybody

PK So – and that certainly data supported this that by was and was the PD. then first supported clinical it

So…

Rusty Williams

effects point to target so and kinase it effect, likely they’ve reported to And tyrosine side related receptor. than that’s that those forward. is then another pexidartinib is block for going drug off CSFX other be that final And are issue inhibitors that kinases

Jim Birchenough

can’t some you other would so those. pancreatic maybe ovarian set a one and rate and you give there’s the Could standard question see cancer line response maybe and if is glioblastoma, pinpointing which context would us one good let pancreatic repair then for the discussed, guys going but you good lower of maybe bar on second And cohort by durability? allow be what us starting current now Helen in you mentioned say think data I been into know we’re SITC, what be you where so with bar has maybe of

Helen Collins

think where be so anything well groups Well, beneficial four three, highlight If when I non-small cell I that lung four response, that durable the did be vitamin, you any think I’m meaningful. speaking PDX it the as I cancer resistant essentially not we’ve are was PDL-X would those could or certainly you’re those been those would see so approved, have or as because right.

cancer, somewhere of I outside quote line chemo low aware is second PFS, that me five has I so months terms efficacy a second would even along say In that, to up. bar but months PDL-X at three great. I look It don’t’ pretty on there’s have so not therapies go mean, line pancreatic why think no I’m survival, or like therapy, IO PDX, the think there to And of. reported a of I I

– be seen then that’s what So, to standard the best what’s I the would want things, you be two alone, Standard with thinking [Indiscernible] right, really same mean, of way bar about Care better about so been the is we thinking what which PDX you

Rusty Williams

people lot and of to really MSI day can unless in and PDX data to conclusion. Yes. setting responses in of these is there’s We all you’re obviously PDX but refocus you gotten cohorts MSI’s all response reach any activity have lot so for thought on the and negative think of to a no we ask pancreatic there that

Jim Birchenough

Great. questions. for taking Thanks

Rusty Williams

welcome. You’re

Operator

you. Thank

question next Our comes from Ian Somaiya Capital. of BMO

is open. now Your line

Ian Somaiya

and there the you congratulations your roles? Rusty on on progress Thank all congratulations and new

Rusty Williams

you. Thank

Ian Somaiya

in goal a SITC, better investigator chemo see we’re your second are in following appreciate just combination. overall And to the to better pancreatic what quickly that was of be cancer Just I data, I the going line conclusion given reaching on is again area think expertise the we current of present standard than just is wanted up to data. care a which

efficacy, different hearing So than presentation would you that? or or obviously is safety sort when of threshold and better comparable consider say of we it the should better sort

Rusty Williams

signal BMS Well, to trial a with we this trial. seeking set be up

interpret so, in trial, And arm, we the any pancreatic there they’re where the and signal our to attribute any than of that one cohorts it, compare settings could kind was where Care, could responses, seeking. that’s that those of discern of be more meaning we it. signal is Standard response and to we no the to to It get you how would terms – any and to seek drug. that’s goal control so cohorts signal kind it And cohorts at in set and of kind if of rate in with in easy you look no so durability with to signal wasn’t a some a just up it other in be signal

Ian Somaiya

steps, chemo. should standard from line, I again sense it because is marketplace chemo? how of ideally Care would And does want line we cancer And away sort therapeutic think a get about if there about combination would evaluate think first make of second next the likely with to you at Right. a to that’s current the

Rusty Williams

and We after step. might you event at right a next now our give the guidance SITC our webcast our presentation. event, can’t We that give little Yes. on color any on at

Ian Somaiya

to earnings in Bristol, the at [Indiscernible] all we to with just where was curious the just transfer sort moving step And of your are that sort of I question, that’s ability to and one larger mentioned Okay. I Cabira? last process, know you limiting last maybe settings call manufacturing responsibility

Rusty Williams

can Yes. Thanks as step is It’s delays as very transfer went no at this done. well. for limiting paying not attention No – to we anticipated. great that. Material point. material far The hick-ups, tell

Ian Somaiya

to if role get Cabira? expect with for Just partner? wanting Okay. just sort one of further a be be the have development, to do final you sense and of your can future your development what And I responsibilities question, your shared how the will in

Aron Knickerbocker

Yes. Hi. It’s Aron.

So, somewhat milestone Five is operationalizing an as that independent you Prime, those and That’s this we’re arrangement. payments program for may we conducting the program treated differently them in studies, recall are of so advances. PVNS eligible

BMS. partners Prime additional do or the in the our wish products that to we Five we however if said, BMS development with would at also subsequent For That in immuno-oncology up be to with either have oncology products. rights studies

it’s would by to well, IO BMS. next step would available that’s be as but so we in most how And us led that expect

Ian Somaiya

you Thank again, are forward looking we Okay. to and Saturday.

Rusty Williams

Thanks.

Operator

you. Thank

comes question Eun next Jefferies. from Yang Our of

Your line is now open.

Eun Yang

FPAXXX, patients there? are enroll for safety Phase to I Phase how when to patients many you. and be Thank planning you in have leading this going push questions so X are to [ph] X, moving how you’re

Rusty Williams

for question. Thanks [ph] views the Helen get let I’ll on Hi. into that.

of number On in patients of leading the the the safety in [ph] number the patients in X. Phase

Helen Collins

on the that and we we starting give inkling should for we we’re Phase So, in I need yet next based that moving middle some then that this previous we don’t but ready the going how will exactly, and start of X you think into now being year. that’s think go, anticipate X many, the my imagine to just response haven’t of you to Phase could fact said closest.

Rusty Williams

we So data Phase chemotherapy, standard a we in the overlap know safety any because as we, of it’s have. escalation with you said, those XXX don’t Helen of already anticipate issues X and

in the think good think to far. it go FPAXXX head way, that’s it otherwise. safety be shown reason so given – we what and relatively a think going we does, surprisingly fact never but of sure, to we we’ve so the profile quickly. to surprisingly data No And

we’re patients towards us on cancer gastric as think that’s we and possible in the metastatic the gets line rapidly. want finish unfortunately we these [ph] of progress In pivotal a this course cancer manner. what Phase it set because in, gastric progress, a we X cancer setting registrational quick and gastric matter. the this help – We We in so show Now that’s a to is power this overall – trial. up survival that different this

this. way think that’s be facilitated with of in and think if of we if go, patients tremendous to and doable. to so that with the see to compare OS you imminently so lot prevail And we the in other and cancer partner plan of a we are by that endpoints, to probably our OS what partner high-quality so speed gastric probably China, Part we enhance or patients number of is do the where the best we China that’s OS will does get

what think period it be of data show and enough That’s we can hope. to able long time OS. So don't to will we it's get an unreasonably take

Eun Yang

the today the survival and additional expectations then how of arm additional or in aiming months trial control for the show? to OS are of many So what’s that weeks you

Helen Collins

Yes.

survival. said the there So that that, XX again, to that supports a clinical I data mean, was a meta-analysis that’s about in literature think Care haven’t overall I its certainly XX we months Standard concurrent [Indiscernible] of

or a but expression you prognosis, FGFR amplification believe X has as that we think know so… I worse FGFR over X

Rusty Williams

standard a control the have cancer these literature that patient. prognosis So data that patients has the are gastric available because arm important, in been show worse all is the

but expect arm it progress for you even you’ll anything regular out cancer patient in there trial this amplification, if the may the without control fast gastric us then the that bad see. so might help we is patient what’s patients So to think for

Eun Yang

[Indiscernible] do one for study? there’s then would U.S.,EU of a and regulatory the submission or Japan do another Japan And trial you factory Okay. to in that need bridging

Helen Collins

have monotherapy support in being trial. right that patients believe is the now we from in Phase Japan that X global Well, to from which we data Japan, involve able a trial and will

Eun Yang

Japan? trial would global to enough the file approval With in an be it

Helen Collins

our is plan. That

Eun Yang

you. Thank

Operator

you. Thank

[Indiscernible]. Our from next question comes

now Your is open. line

Unidentified Analyst

we been Rusty, questions much. Great. can’t out. and appreciate Thanks Aron have to continue All seek And hide But asked. from very you it. we’ll the Rusty us, congratulations you

Rusty Williams

hide. want wouldn’t to you, Chris. Thank I

Unidentified Analyst

Helen, the basically is for try which and the no completed ring possibly represents Is decoder Aron option? put me this if So on quickly an that in treatment look indication there Rusty, at to word interpret enrolment cohort. to we fair

Rusty Williams

which the tremendous, there’s product there’s need. hate I but guess words unmet I same a the says Well, tremendous thing.

Helen Collins

The investigators had believed it.

Rusty Williams

Tremendous unmet. Yes.

Unidentified Analyst

interpret how still the versus think to Cabira? benefit? Can trying sticking we plus should you or the backbone data about of PDX arm the over benefit biomarker we then prospect how Cabira And PDX the could to trial, contributing what interpret from study component about the Okay. obviously derives really to of single what’s talk

Rusty Williams

Yes.

and you for therapy on therapy, other then been slightly I its that’s any interpretation think et see than us those. PDX cohorts And PDX there by really no the meaningful. and to where those field you an responses an then already [ph] that. failed, it in can PDX response is three the make indication is response – the I answer PDX example, could cohort less cetera, responses think people the lack is have BMS there’s to in cleanest blockers, indication meaningful either it or pathway is where also clean no through to that Obviously there interesting failed [Indiscernible] have where but look you that where response for and where in maybe broken cohorts people are interpreted in way, see

terms data the a kind Nivo. Cabira of that’s And we way at in assessing contribution that’s of of so versus -- the look

Unidentified Analyst

the finally permit—permitting I data then guess And represent to you SITC at Okay. from Analyst meeting arm. our understanding

might Meeting to in will evening how we’ll about fuller cohorts that data late additional just you’re you. half of ones come Thank at present able beyond say breaker? Saturday second the the Analyst data on did in You XXXX, but other from get your be

Rusty Williams

present plan is meeting those XX all data presentation. than we It in the the and to has sticking able preps that afterwards been event along get be we’re more to the our can to SITC the data at analyst minute to color to plan to

have plan haven’t to that this we those we we cohort disclosures And where are, that so we’re more disclosing to first we go think one going data and cohort. we're so and contacts stick to we of later kind in a had beyond because

Unidentified Analyst

guys. you, Thanks Great. Okay.

Rusty Williams

stick other to do. that’s settings but as because At we medical disclose conference Aron going in to, we we to what think data, this and alluded one other we’re cohort agree BMS will that one to the

Unidentified Analyst

you. Thank

welcome. You’re

Operator

Thank you.

Our Marai Instinet. Nomura next question of comes from Christopher

Your is open. now line

Christopher Marai

questions. the taking for Thanks Hey.

that what is data look last walk Obviously Just a fully then make about SITC combination, the versus about through the be bit you combination there tease the lot wonder trigger out next contribution little could all And chemo flush you’ve how the I to to bit if not in obviously I studies. thinking to a to you [Indiscernible] a before relative data little move touch report of from studies. sense. maybe upon may may nivo. secondarily just this new out so you combo us one Thinking here. mean been need

line? line Thanks. in those? maybe might secondarily to when then be see expect So And just required that front across you’d FOLFOX we the finish to the that benefit versus get the

Helen Collins

meaningful, each to have individual something -- some. so control maybe benefit we said XXX by I I’m one looking evasive and type The type is sound that statistically so on are you components survival is of each I no it’s at tumor I it this on and dependent the patients terms it’s it’s overall characteristics I’ll week not – biomarkers going mean, we’re think sorry much I the very going somewhat the that’s tumor to think believe will of so to Rusty. the XX% tumor in significant how helping individual we to we’re into be We mean well can of again, population. move of the dependent. clinically forward answer show form going combo type being So, rest, Cabira endpoint to therapy, but there in – go or or of Go both first. don’t all and very be patient are ahead we excuse me think those just study that design and think if things of prior designing the you and a specific know what the OS we that as as tumor that’s

Rusty Williams

Chris. Hi,

combinations that Cabira with also your were asking you about question? think of other I agents. Is

Christopher Marai

to some may out. trigger decisions, could are combinations, full see be to be obviously [Indiscernible] those Yes. read that data not you those of guys going developing inform those the and you

Rusty Williams

agents question for using with So good in have answer There combination to Cabira other PD-X broadly. blockers. rationale I’ll is pathway other the than

trial have in ovarian You they Anderson with good see they already Avastin done agonist. there so with combination Roche doing a Roche has M.D. chemo doing they that cloud; a recently plus T-Cell have Bevacizumab CDXX, roughly CSF-X started antibody, are rationale. with receptor have receptor the at their anti disclosed antibody. They and is cancer plus and looking what also CSF-X

that BMS was in in an for remember discussion with pipeline. in with you we our issue we As in with important have agreement to BMS sit our a that do the in right including up our those combination other Cabira agents our at beginning. work And

there so rational. good is a And

yet it. We to prepared yet disclosed but are good what for not it’s consider, that have we a might not are combinations disclose and rational the

Christopher Marai

just of some then triggering data Great and a of you to combination need start level that those studies?

Rusty Williams

third kind studies in to we in not from about some that tumor doing to a a lot a the that the down, designing the respect we we’ve the have product probably long we’ve because this combination. to that cohort. I so high. And we’ve the it’s of lot. response way with of we threshold, think learnt of – reported for safety. responses lot earned the have of we’ve from think design think things the for that to markers might of We we contribute Those think understand a important you sufficient biomarker [Ph] of hard up threshold information be patients a a based on and combination to have about think got Well obviously process biomarkers a case from thoughts, a it’s We understand different us. terms drug we the is pin that in the will data and a we dose with another And We’ve environment conclusion We’ve the terms about come a analyzing respect in that know PK, done learnt micro of lot that. Xb a those I in in dose.

Christopher Marai

Got it. [Indiscernible] of of just terms types trials. in And

Rusty Williams

by been so potential Thank Analyst along started pivotal And referring are And we to you think Got see guess those and we what clinical guess pre wouldn’t designs. these work for to with respect do you. on when be combinations, I could specifically when combination, a have start, have able those the and other obviously really going to be working with or might might pivotal I in we then trial, just trials you there it. indicated this? so

Rusty Williams

Yes, guidance we haven’t yet. given on that any

really So sorry now. predict can’t guidance. right that give Can’t I really

Christopher Marai

started? trial Sooner or pivotal later than the

Rusty Williams

I it. can’t, I Analyst can’t. Got

I tried. you for my Okay, taking question. Thank

Rusty Williams

I I say think pivotal that’s one waiting are questions, if mean any against are trials it sooner, it I for because means of answer waiting give. we those means that could me turn for Might I later, on we But its time. combination. then

on lady a we got are everything. freezing, have We a hurry in

So your the throughout a combination. very – a There one. good broad is is but the rational point

on of this. ahead get So myself

Christopher Marai

Got it. Thank you.

Rusty Williams

Yes.

Operator

you. Thank

Our next question Securities. of comes from Guggenheim Tony Butler

Your open. now is line

Tony Butler

much. very thanks Hi,

burden why CSFXR or very data be study? by B, you by finally biomarkers, then I reference reason [Ph] but be to squeeze over will much. XXX discuss I XX to have point a segregated this sorry, you can And tumor And XXX, tumor you in, Thanks -- a on made and missed a I’m onto you basket move rotational segregated would and prioritized this, is that? for maybe on You’ve you TMB? patients it is said can , had there

Rusty Williams

priority, on matter in respect so part. both last big reasons. let Helen we we two forward high So them and a one simply With different of and before ahead. to been both, matter a both and of are hurry just and started like let of And are projects timing. I’ll Priortization of are XXX us. – Helen... let that a started in moving them let of start which me markers follow over we was for Tony, TMB, priority on these for we and They high both it’s the then XXX, we’ve XXX We’ve XXX, me

Tony Butler

trial. a about ...question basket

Rusty Williams

BX-HX for trial Basket

Helen Collins

we few how So exactly a haven’t designed. of going X quite thought trial so the designs, about spoken was different to trial be phase

I’m.... So

Rusty Williams

the know the get you the but right think That’s are premature. that I the haven’t number to about – of thinking over a this. do you tumors, the know do this heart number a we track. always know is right tumor expressed on of basket, way matter so we you for so mean concept, that’s of We thinking, I it’s the in disclosed and anything are on that But we

you think correctly. I So that thinking are about

Tony Butler

TMB? the And helpful. That’s

Helen Collins

TMB, so PD-X with thing, so as we that we tumor nivolumab again mean looking And responses is that’s the be that so know types to certain that that something and haven’t at. is you would what alone particularly we that an something at, said is are although looking obvious associated some or are biomarkers exactly

Tony Butler

Thanks. was helpful. That

Rusty Williams

you Tony. thank Yes,

Operator

to And you. turn does and conclude call back our question any answer closing session. the for Thank over this would to like remarks Rusty I now Williams

Rusty Williams

support of further questions. calls. well on look again. updating you Okay, your all thanks each your you to for forward joining today and us We Thanks and for good

Operator

program. today's conference. concludes thank the gentlemen, for Ladies you participation in This and

now You a may disconnect. great day. Everyone, have

Five Prime Therapeutics (FPRX) 6 Nov 172017 Q3 Earnings call transcript